or Try an Advanced Search...

    Technical Analysis for IKNA - Ikena Oncology, Inc.

    Grade Last Price % Change Price Change
    C 1.70 1.19% 0.02
    IKNA closed up 1.19 percent on Wednesday, November 20, 2024, on 33 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Flat Down
    Historical IKNA trend table...
    Date Alert Name Type % Chg
    Boomer Buy Setup Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Oversold Stochastic Weakness 0.00%
    MACD Bearish Centerline Cross Bearish 1.19%
    1,2,3 Pullback Bullish Bullish Swing Setup 1.19%
    Doji - Bullish? Reversal 1.19%
    Lower Bollinger Band Walk Weakness 1.19%
    Stochastic Reached Oversold Weakness 1.19%
    Lower Bollinger Band Touch Weakness 1.19%
    Oversold Stochastic Weakness 1.19%
    Older End-of-Day Signals for IKNA ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    Possible Inside Day about 17 hours ago
    60 Minute Opening Range Breakout about 19 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    Up 1% 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IKNA Chart by TradingView
    Basic chart:

    Profile

    Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Biology Oncology Colorectal Cancer Signal Transduction Cancer Therapies Transcription Factors Novel Cancer

    Is IKNA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 3 US Penny Stocks With Market Caps Over $40M To Consider
    Nov 9 Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)
    Nov 7 Ikena Oncology GAAP EPS of -$0.21 beats by $0.06
    Nov 7 Ikena Oncology Reports Third Quarter 2024 Financial Results
    Aug 9 Ikena Oncology GAAP EPS of -$0.28
    Aug 8 Ikena Oncology Reports Second Quarter 2024 Financial Results
    Jul 12 Best Momentum Stocks to Buy for July 12th
    Jun 1 It's Unlikely That Ikena Oncology, Inc.'s (NASDAQ:IKNA) CEO Will See A Huge Pay Rise This Year
    May 29 Wedbush downgrades Ikena, cites discontinuation of lead asset
    May 28 Ikena to cut workforce by 53%, explore strategic options
    See more IKNA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.32
    52 Week Low 1.22
    Average Volume 47,914
    200-Day Moving Average 1.58
    50-Day Moving Average 1.71
    20-Day Moving Average 1.71
    10-Day Moving Average 1.72
    Average True Range 0.05
    RSI (14) 47.92
    ADX 33.91
    +DI 19.51
    -DI 12.34
    Chandelier Exit (Long, 3 ATRs) 1.64
    Chandelier Exit (Short, 3 ATRs) 1.81
    Upper Bollinger Bands 1.76
    Lower Bollinger Band 1.67
    Percent B (%b) 0.35
    BandWidth 5.53
    MACD Line 0.00
    MACD Signal Line 0.00
    MACD Histogram -0.0049
    Fundamentals Value
    Market Cap 82.04 Million
    Num Shares 48.3 Million
    EPS -1.62
    Price-to-Earnings (P/E) Ratio -1.05
    Price-to-Sales 4.84
    Price-to-Book 0.43
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.75
    Resistance 3 (R3) 1.74 1.72 1.74
    Resistance 2 (R2) 1.72 1.71 1.72 1.73
    Resistance 1 (R1) 1.71 1.70 1.72 1.72 1.73
    Pivot Point 1.69 1.69 1.69 1.69 1.69
    Support 1 (S1) 1.68 1.68 1.69 1.69 1.67
    Support 2 (S2) 1.66 1.67 1.66 1.67
    Support 3 (S3) 1.65 1.66 1.66
    Support 4 (S4) 1.66